@article{0ca784a269dd49a785bba576d21fed88,
title = "Drug repurposing approach to combating coronavirus: Potential drugs and drug targets",
abstract = "In the past two decades, three highly pathogenic human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus, and, recently, SARS-CoV-2, have caused pandemics of severe acute respiratory diseases with alarming morbidity and mortality. Due to the lack of specific anti-CoV therapies, the ongoing pandemic of coronavirus disease 2019 (COVID-19) poses a great challenge to clinical management and highlights an urgent need for effective interventions. Drug repurposing is a rapid and feasible strategy to identify effective drugs for combating this deadly infection. In this review, we summarize the therapeutic CoV targets, focus on the existing small molecule drugs that have the potential to be repurposed for existing and emerging CoV infections of the future, and discuss the clinical progress of developing small molecule drugs for COVID-19.",
keywords = "COVID-19, MERS-CoV, SARS-CoV, SARS-CoV-2, anti-CoV, coronavirus, drug repurposing, drug targets, small molecule drugs",
author = "Jimin Xu and Yu Xue and Richard Zhou and Shi, {Pei Yong} and Hongmin Li and Jia Zhou",
note = "Funding Information: This study was partially supported by grants AI131669, AI140726, and AI141178 from the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (Hongmin Li and Jia Zhou). Jia Zhou is also partly supported by John D. Stobo, the M.D. Distinguished Chair Endowment Fund, and the John Sealy Memorial Endowment Fund at UTMB. Hongmin Li is additionally supported by NIH grants AI133219, AI134568, AI140406, and AI140491. Pei-Yong Shi was supported by NIH grants AI142759, AI134907, and AI145617, UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, John S. Dunn Foundation, Amon G. Carter Foundation, Gilson Longenbaugh Foundation, and Summerfield Robert Foundation. Funding Information: This study was partially supported by grants AI131669, AI140726, and AI141178 from the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (Hongmin Li and Jia Zhou). Jia Zhou is also partly supported by John D. Stobo, the M.D. Distinguished Chair Endowment Fund, and the John Sealy Memorial Endowment Fund at UTMB. Hongmin Li is additionally supported by NIH grants AI133219, AI134568, AI140406, and AI140491. Pei‐Yong Shi was supported by NIH grants AI142759, AI134907, and AI145617, UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, John S. Dunn Foundation, Amon G. Carter Foundation, Gilson Longenbaugh Foundation, and Summerfield Robert Foundation. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",
year = "2021",
month = may,
doi = "10.1002/med.21763",
language = "English (US)",
volume = "41",
pages = "1375--1426",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "3",
}